DOI: 10.36347/sasjm.2023.v09i09.006

Pages: 935-940

The management of esthesioneuroblastoma presents unique challenges due to its rarity and complex nature. This malignant tumor originating from the nasal cavities requires a comprehensive and multidisciplinary approach. Our retrospective study focuses on shedding light on the distinctive aspects of managing this uncommon condition based on our experience at the Radiotherapy Oncology Department of Mohammed VI University Hospital in Marrakech, Morocco, over a 6-year period from 2016 to 2021. The majority of the patients in our cohort were male, constituting 60% of the cases, resulting in a male-to-female ratio of 1.5. The mean age at diagnosis was 25.8 years, highlighting that this condition can affect individuals in their prime years of life. Clinical and paraclinical data analysis revealed that 80% of the patients were classified as Kadish stage C, indicating advanced disease, while 20% were categorized as Kadish stage D, reflecting even further progression. As for patient management, it involved a multimodal treatment approach combining surgery with adjuvant radiotherapy in 3 patients, radiotherapy with chemotherapy in one patient, and a combination of all three therapeutic modalities in one patient. Survival outcomes were modest, with a median survival of 15 months. The aggressive nature of esthesioneuroblastoma requires a proactive and collaborative approach involving oncologists, surgeons, radiation therapists, and pathologists. The rarity of this tumor underscores the importance of knowledge-sharing and collaborative efforts among medical professionals to establish standardized guidelines for its management.